.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,582,918

« Back to Dashboard

Details for Patent: 6,582,918

Title: Platelet derived growth factor (PDGF) nucleic acid ligand complexes
Abstract:This invention discloses a method for preparing a complex comprised of a PDGF Nucleic Acid Ligand and a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound by identifying a PDGF Nucleic Acid Ligand by SELEX methodology and associating the PDGF Nucleic Acid Ligand with a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound. The invention further discloses Complexes comprising one or more PDGF Nucleic Acid Ligands in association with a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound. The invention further includes a Lipid construct comprising a PDGF Nucleic Acid Ligand or Complex and methods for making the same.
Inventor(s): Janjic; Nebojsa (Boulder, CO), Gold; Larry (Boulder, CO)
Assignee: Gilead Sciences, Inc. (Foster City, CA)
Filing Date:May 08, 2001
Application Number:09/851,486
Claims:1. A method for treating a patient having a PDGF mediated disease or medical condition comprising administering to a patient in need thereof a pharmaceutically effective amount of a Complex comprised of a PDGF Nucleic Acid Ligand and a Non-Immunogenic, High Molecular Weight Compound or a Lipophilic Compound.

2. The method of claim 1 wherein said Complex further comprises a Linker between said Ligand and said Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound.

3. The method of claim 1 wherein said Ligand comprises a Linker.

4. The method of claim 1 wherein said Non-Immunogenic, High Molecular Weight Compound is a Polyalkylene Glycol.

5. The method of claim 4 wherein said Polyalkylene Glycol is polyethylene glycol.

6. The method of claim 5 wherein said polyethylene glycol has a molecular weight of about between 10-80 K.

7. The method of claim 5 wherein said polyethylene glycol has a molecular weight of about 20-45 K.

8. The method of claim 4 wherein said Complex has the structure ##STR3##

9. The method of claim 1 wherein said Lipophilic Compound is a glycerol lipid.

10. The method of claim 9 wherein said Complex is associated with a lipid construct.

11. A method of inhibiting PDGF mediated angiogenesis comprising: covalently linking a PDGF Nucleic Acid Ligand to a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound to form a Complex; and administering said Complex to a patient having a disease or condition comprising PDGF mediated angiogenesis.

12. A method of inhibiting the growth of tumors comprising: covalently linking a PDGF Nucleic Acid Ligand to a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound to form a Complex; and administering said Complex to a patient having a disease or condition comprising tumors expressing PDGF.

13. The method of claim 12 wherein said tumors or cells or tissues surrounding said tumors are expressing PDGF.

14. The method of claim 12 wherein said tumors or cells or tissues surrounding said tumors are expressing PDGF receptors.

15. A method of inhibiting fibrosis comprising: covalently linking a PDGF Nucleic Acid Ligand to a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound to form a Complex; and administering said Complex to a patient having a disease or condition comprising fibrosis.

16. The method of claim 15 wherein said Complex further comprises a Linker between said Ligand and said Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound.

17. The method of claim 15 wherein said Ligand comprises a Linker.

18. The method of claim 15 wherein said fibrosis is kidney fibrosis.

19. The method of claim 15 wherein said fibrosis is lung fibrosis.

20. The method of claim 15 wherein said fibrosis is bone marrow fibrosis.

21. The method of claim 15 wherein said fibrosis is radiation treatment-associated fibrosis.

22. The method of claim 16 wherein said Non-Immunogenic, High Molecular Weight Compound is a polyalkylene glycol.

23. The method of claim 22 wherein said polyalkylene glycol is polyethylene glycol.

24. The method of claim 23 wherein said polyethylene glycol has a molecular weight of about between 10-80k.

25. The method of claim 23 wherein said polyethylene glycol has a molecular weight of about between 20-45k.

26. The method of claim 25 wherein said complex has the structure ##STR4##

27. A method of inhibiting restenosis comprising: covalently linking a PDGF Nucleic Acid Ligand to a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound to form a Complex; and administering said Complex to a patient having a disease or condition comprising restenosis.

28. The method of claim 27 wherein said Complex further comprises a Linker between said Ligand and said Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound.

29. The method of claim 27 wherein said Ligand comprises a Linker.

30. The method of claim 27 wherein said Non-Immunogenic, High Molecular Weight Compound is a polyalkylene glycol.

31. The method of claim 30 wherein said polyalkylene glycol is polyethylene glycol.

32. The method of claim 31 wherein said polyethylene glycol has a molecular weight of about between 10-80k.

33. The method of claim 31 wherein said polyethylene glycol has a molecular weight of about between 20-45k.

34. The method of claim 33 wherein said complex has the structure ##STR5##

35. The method of claim 27 wherein said restenosis is in-stent restenosis.

36. The method of claim 27 wherein said restenosis is in a coronary artery.

37. The method of claim 27 wherein said restenosis is in a non-coronary vessel.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc